Appearance of neuropeptides in ascitic fluid after peritoneal therapy with interleukin-2 and lymphokine-activated killer cells for intraabdominal malignancy
- 1 March 1989
- journal article
- research article
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 9 (2) , 169-173
- https://doi.org/10.1007/bf00916945
Abstract
Administration of intravenous interleukin-2 (IL-2), followed by intraperitoneal IL-2 and autologous lymphokine-activated killer (LAK) cells to six patients with colonic, ovarian, or endometrial carcinoma restricted to peritoneal spread increased significantly the ascitic fluid concentrations of the neuropeptides substance P (SP) and calcitonin-gene related peptide (CGRP). After intravenous IL-2 alone, the level of SP rose 10- to 140-fold, without a change in that of CGRP. Intraperitoneal IL-2 and LAK cells led to elevations in the concentrations of SP and CGRP to respective maximal means of 319 and 175 pM after 8 hr, which were maintained for 24–48 hr without alterations in the levels of vasoactive intestinal peptide or somatostatin. SP and CGRP from peritoneal fluid were chromatographically indistinguishable from synthetic neuropeptides. The increases in concentrations of SP and CGRP after IL-2 and LAK-cell therapy are the first demonstration of a neural response to a human cellular immunological reaction. The time course and magnitude of the neuropeptide response suggest a role in the vascular side effects of this form of treatment.This publication has 14 references indexed in Scilit:
- Distinctive patterns of release of neuroendocrine peptides after nasal challenge of allergic subjects with ryegrass antigenJournal of Clinical Immunology, 1988
- Selective localization of vasoactive intestinal peptide and substance P in human eosinophilsBiochemical and Biophysical Research Communications, 1987
- Airway neuropeptides and asthmaTrends in Pharmacological Sciences, 1987
- High-Dose Recombinant Interleukin 2 in the Treatment of Patients With Disseminated CancerJAMA, 1986
- Intraperitoneal Administration of Interleukin-2 in Patients With CancerArchives of Surgery, 1986
- ANTITUMOR EFFICACY OF LYMPHOKINE-ACTIVATED KILLER-CELLS AND RECOMBINANT INTERLEUKIN-2 INVIVO - SUCCESSFUL IMMUNOTHERAPY OF ESTABLISHED PULMONARY METASTASES FROM WEAKLY IMMUNOGENIC AND NONIMMUNOGENIC MURINE TUMORS OF 3 DISTINCT HISTOLOGICAL TYPES1986
- Potent Vasodilator Activity of Calcitonin Gene-Related Peptide in Human SkinJournal of Investigative Dermatology, 1986
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.The Journal of Immunology, 1985
- The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo.The Journal of Immunology, 1985